KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-Current Assets (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Non-Current Assets for 17 consecutive years, with $3.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 3.09% year-over-year to $3.6 billion, compared with a TTM value of $7.1 billion through Dec 2025, down 53.33%, and an annual FY2025 reading of $3.6 billion, down 3.09% over the prior year.
  • Non-Current Assets was $3.6 billion for Q4 2025 at Biomarin Pharmaceutical, up from -$3.9 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $3.9 billion in Q1 2024 and bottomed at -$3.9 billion in Q3 2025.
  • Average Non-Current Assets over 5 years is $2.9 billion, with a median of $3.7 billion recorded in 2021.
  • The sharpest move saw Non-Current Assets surged 260.29% in 2022, then crashed 201.58% in 2025.
  • Year by year, Non-Current Assets stood at $3.7 billion in 2021, then dropped by 2.86% to $3.6 billion in 2022, then grew by 7.23% to $3.9 billion in 2023, then fell by 3.32% to $3.8 billion in 2024, then fell by 3.09% to $3.6 billion in 2025.
  • Business Quant data shows Non-Current Assets for BMRN at $3.6 billion in Q4 2025, -$3.9 billion in Q3 2025, and $3.7 billion in Q2 2025.